Kamada (KMDA) Non-Current Deferred Tax Liability (2024 - 2026)
Kamada's (KMDA) quarterly Non-Current Deferred Tax Liability came in at $3.8 million in Q2 2026, up 479.67% on a YoY basis from $659000.0 in Q2 2025, and up 33.29% quarter-over-quarter from $2.9 million in Q1 2026.
Analysis
Kamada (KMDA) Non-Current Deferred Tax Liability (2024 - 2026) Analysis & Trends
Kamada (KMDA) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $3.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Deferred Tax Liability rose 479.67% year-over-year to $3.8 million; the trailing twelve-month figure through Jun 2026 stood at $3.8 million (up 479.67% YoY), and the FY2025 full-year result was $1.7 million, up 99900.0% from the prior year.
- Non-Current Deferred Tax Liability climbed to $3.8 million in Q2 2026 per KMDA's latest filing, from $2.9 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $3.8 million in Q2 2026 and bottomed at $1651.0 in Q4 2024.
- Historically, Non-Current Deferred Tax Liability has averaged $1.8 million across 3 years, with a median of $1.7 million in 2025.
- The sharpest annual moves came in 2025 and 2026: Non-Current Deferred Tax Liability jumped 99900.0% in 2025, then surged 39.06% in 2026.
- Over 3 years, Non-Current Deferred Tax Liability stood at $1651.0 in 2024, then surged by 99900.0% to $1.7 million in 2025, then jumped by 131.37% to $3.8 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.8 million, $2.9 million, and $1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.82 Mn |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 659,000.00 |
| Mar 31, 2025 | 2.06 Mn |
| Dec 31, 2024 | 1,651.00 |